Cannabis Europa is proud to announce Dragonfly Biosciences as a Bronze Partner for our Paris conference on February 8th.

Dragonfly Biosciences is Europe’s largest and leading producer of Cannabidiol (CBD) and cannabis-derived extracts. After rapid growth in the past two years, it now boasts a head office in London, farms and formulation facilities in Bulgaria, and partner companies in Poland, Canada and Malta. A seed-to-sale producer, Dragonfly’s reach is bolstered by 420 hectares of organically certified, fully irrigated farmland – a capacity soon to rise.

Cannabis Europa will bring together European industry leaders like Dragonfly Biosciences to the table with policymakers, scientists and patient advocates to discuss the latest developments in European cannabis policy. This mélange of stakeholders and political actors with the inside track on developing regulatory processes will discuss solutions to the opaque and convoluted legal status of cannabidiol in Europe.

Quality and Transparency at the Forefront

Dragonfly Biosciences prides itself on quality and transparency. All of its extracts are certified vegan, non-GMO, THC free, organic and formulated in a GMP facility. All relevant documentation – from organic certificate to HPLC tests – is made visible to consumers on the DragonflyCBD website. Dragonfly’s transparent approach forms one of the company’s major aims – to revolutionise and legitimise the European cannabis industry. In order to bring about such change, Dragonfly believes that change in regulation and attitudes is the only way to push the cannabis industry forward.

IMG-20190118-WA0001 (1).jpg

“Dragonfly is incredibly excited for Cannabis Europa, an event that connects policymakers, lobbyists and growers and in turn, will drive the cannabis industry forward.”

Hannah Skingle, COO and Speaker at Cannabis Europa Paris

CBD’s Place in Europe

Cannabis Europa Paris will facilitate discussions on the intricacies of CBD production and regulation in Europe, a continent traditionally strong in hemp cultivation and export. Panels will discuss the regulation of the market and attempt to bridge the gap between medical cannabis access and new legislation. Attendees will be able to attend talks on how novel EU legislation will affect CBD, ways to increase government-level understanding of medical cannabis and CBD products, and prospects for partnership in the cosmetics industry.

If you wish to join the conversation on 8th February at Maison de la Chimie, book today, limited tickets remaining.


Related posts